GlassScriptPhysician profile
Jasmine Jamerson
NPI 1013789148
$1,197.45
in general payments reported to CMS, 2019-2025
13 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $685 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.96 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $257.89 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $218.81 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.52 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $171.67 | 2024-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $137.26 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $65.08 | 2024-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $41.37 | 2024 | |
| Collegium Pharmaceutical, INC. | $31.08 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $23.38 | 2025 | Spravato |
| Noven Therapeutics, LLC | $20.90 | 2024 | Xelstrym |
| Noven Pharmaceuticals, INC. | $17.94 | 2024 | Xelstrym |
| Axsome Therapeutics, INC. | $15.48 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $14.07 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Jamerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.